Literature DB >> 28716526

SLC45A3-ELK4 functions as a long non-coding chimeric RNA.

Fujun Qin1, Yanmei Zhang2, Jia Liu1, Hui Li3.   

Abstract

Gene fusions in cancer typically lead to the expression of a fusion protein or disrupt the expression of one of the parental genes. Here we report a new phenomenon whereby a fusion transcript functions as a long non-coding chimeric RNA (lnccRNA). This fusion RNA, SLC45A3-ELK4, generated by cis-splicing between neighboring genes, was found in prostate cancer. The fusion RNA encodes the same protein as ELK4. Intriguingly, we found that the fusion RNA level is less than 1% of wild type ELK4, unlikely to perturb the general pool of ELK4 protein. Nonetheless, when the fusion RNA, but not ELK4 is silenced, cell proliferation is inhibited in both androgen-dependent and castration-resistant prostate cancer cells. This growth arrest can be rescued by exogenous expression of the fusion and a mutant designed to prevent translation of the ELK4 protein. In the same setting, the mutant could also suppress CDKN1A and several other targets of SLC45A3-ELK4. In addition, similar to many long non-coding RNAs, the fusion RNA is enriched in the nuclear fraction. Altogether, these results indicate that SLC45A3-ELK4 regulates cancer cell proliferation by its transcript, not translated protein.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chimeric RNA; Long non-coding RNA; Prostate cancer; SLC45A3-ELK4; cis-SAGe

Mesh:

Substances:

Year:  2017        PMID: 28716526     DOI: 10.1016/j.canlet.2017.07.007

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  17 in total

1.  Multiple information carried by RNAs: total eclipse or a light at the end of the tunnel?

Authors:  Baptiste Bogard; Claire Francastel; Florent Hubé
Journal:  RNA Biol       Date:  2020-06-26       Impact factor: 4.652

Review 2.  Chimeric RNAs and their implications in cancer.

Authors:  Zi Li; Fujun Qin; Hui Li
Journal:  Curr Opin Genet Dev       Date:  2017-11-05       Impact factor: 5.578

Review 3.  Chimeric RNA in Cancer and Stem Cell Differentiation.

Authors:  Justin Elfman; Hui Li
Journal:  Stem Cells Int       Date:  2018-10-28       Impact factor: 5.443

4.  The fusion landscape of hepatocellular carcinoma.

Authors:  Chengpei Zhu; Liangcai Wu; Yanling Lv; Jinxia Guan; Xue Bai; Jianzhen Lin; Tingting Liu; Xiaobo Yang; Simon C Robson; Xinting Sang; Chenghai Xue; Haitao Zhao
Journal:  Mol Oncol       Date:  2019-04-11       Impact factor: 6.603

Review 5.  A New Era of Prostate Cancer Precision Medicine.

Authors:  Adil Malik; Srilakshmi Srinivasan; Jyotsna Batra
Journal:  Front Oncol       Date:  2019-11-26       Impact factor: 6.244

6.  Non-coding RNAs in cancers with chromosomal rearrangements: the signatures, causes, functions and implications.

Authors:  Cai Han; Lin-Yu Sun; Wen-Tao Wang; Yu-Meng Sun; Yue-Qin Chen
Journal:  J Mol Cell Biol       Date:  2019-10-25       Impact factor: 6.216

7.  The relationship between chimeric RNAs and gene fusions: Potential implications of reciprocity in cancer.

Authors:  Justin Elfman; Lam-Phong Pham; Hui Li
Journal:  J Genet Genomics       Date:  2020-06-14       Impact factor: 5.723

Review 8.  Pathological bases and clinical impact of long noncoding RNAs in prostate cancer: a new budding star.

Authors:  Tao Xu; Chang-Ming Lin; Shu-Qi Cheng; Jie Min; Li Li; Xiao-Ming Meng; Cheng Huang; Lei Zhang; Zi-Yu Deng; Jun Li
Journal:  Mol Cancer       Date:  2018-07-23       Impact factor: 27.401

9.  TAP: a targeted clinical genomics pipeline for detecting transcript variants using RNA-seq data.

Authors:  Readman Chiu; Ka Ming Nip; Justin Chu; Inanc Birol
Journal:  BMC Med Genomics       Date:  2018-09-10       Impact factor: 3.063

10.  The landscape of chimeric RNAs in non-diseased tissues and cells.

Authors:  Sandeep Singh; Fujun Qin; Shailesh Kumar; Justin Elfman; Emily Lin; Lam-Phong Pham; Amy Yang; Hui Li
Journal:  Nucleic Acids Res       Date:  2020-02-28       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.